Cargando…
Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer
The interleukin 6 (IL-6)/glycoprotein 130 (GP130)/signal transducer and activator of transcription 3 (STAT3) signalling pathway, with GP130 as an intermediate membrane receptor, is involved in the survival, metastasis, and resistance of ovarian cancer. Bazedoxifene, an FDA-approved drug, is an inhib...
Autores principales: | Park, Sun-Ae, Kim, Lee Kyung, Park, Hye Min, Kim, Hee Jung, Heo, Tae-Hwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771159/ https://www.ncbi.nlm.nih.gov/pubmed/35029286 http://dx.doi.org/10.3892/or.2022.8263 |
Ejemplares similares
-
Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer
por: Kim, Leekyung, et al.
Publicado: (2021) -
Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy
por: Wei, Jia, et al.
Publicado: (2019) -
Correction to: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy
por: Wei, Jia, et al.
Publicado: (2019) -
Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy
por: Xiao, Hui, et al.
Publicado: (2017) -
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer
por: Heo, Tae-Hwe, et al.
Publicado: (2016)